Polycystic Kidney Disease Market

SKU: DM2225 | Last Updated On: Sep 06 2022 | Available Formats

> Polycystic Kidney Disease Market Expected to reach a high CAGR of 4.3% By 2029: DataM Intelligence

Polycystic Kidney Disease Market is segmented By Product Type (Autosomal dominant polycystic kidney disease, Autosomal recessive polycystic kidney disease), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Polycystic Kidney Disease Market size was valued US$ 450.5 million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.3% during the forecast period (2022-2029).

Polycystic Kidney Disease Market Scope

Metrics

Details

Market CAGR

4.3%

Segments Covered

By Type, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get a Free sample click here

The genetic ailment known as polycystic kidney disease is a genetic disease that forms cysts in the kidneys and causes malfunction in the kidneys. There are some health problems related to it such as renal failure and high blood pressure. Polycystic kidney disease is highly dangerous chronic disease of kidney. It gets very tough for kidneys to filter waste from blood as these formed cysts enlarges the kidneys.

Market Dynamics

In recent time, the increase in the kidney diseases and various novel technological innovations along with government initiatives for awareness of these diseases are the factors that are fueling the growth of market.

The prevalence of special regulatory designations and technological Innovations in polycystic kidney disease are expected to drive market growth.

The global polycystic kidney disease treatment market is projected to be propelled by technological advancements, leading to the development of a wide array of drugs, which will enable clinicians to provide better assistance to polycystic kidney disease patients. For instance, in July 2018, Reata Pharmaceuticals, Inc. announced positive phase II data for bardoxolone methyl for chronic kidney disease caused by alport syndrome and autosomal dominant polycystic kidney disease.

PKD is prevalent in both developed and developing countries and affects all racial and ethnic groups equally. Government initiatives to spread awareness by implementing different programs about PKD is projected boost the growth of the global polycystic kidney disease treatment market. For instance, PKD Foundation invested over US$ 40 Mn in basic and clinical research grants for PKD diagnosis. However, less awareness in the underdeveloped countries and high cost associated with the treatment are likely to hamper the growth of the global polycystic kidney disease treatment market in the next few years.

The prevalence of special regulatory designations is one of the key drivers supporting the growth of the global polycystic kidney disease drugs market. The orphan products grants program (OPGP) funds the clinical research tests to check the efficacy and safety of drugs. Organizations such as the US FDA and EMA provide companies with market exclusivity for drugs that they manufacture for a certain period. These drug manufacturers also enjoy benefits such as tax credits for clinical trials and protocol assistance.

High cost of treatment and lack of trained professionals are expected to hamper the market growth.

The cost of the treatment of polycystic kidney disease is very high that is the main restraining factor. Another one is shortage of trained professionals as there is huge demand of professionals but lack in market is also a restraint. These are some factors that will hamper the growth of polycystic kidney disease market.

Industry Analysis

The global polycystic kidney disease market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Epidemiology, Unmet Needs, Product Innovations.

Segment Analysis

Type segment is expected to hold the largest market share in global polycystic kidney disease market

Based on Type market is segmented into:

  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Autosomal recessive polycystic kidney disease (ARPKD)

The two primary types of PKD are autosomal dominant PKD and autosomal recessive PKD. These two forms of PKDs are distinguished by the usual age of onset and the pattern in which it is passed through families. According to the PKD Foundation, autosomal dominant polycystic kidney disease affects more than 600,000 people in the U.S. and 12.4 million people globally. Autosomal recessive polycystic kidney disease is a rare form of the disease that occurs in 1 in 20,000 children across the world.

ADPKD held the largest global PKD drugs market share in 2021. It will remain the leading market shareholder in 2029. ADPKD is the most common form of PKD and increasing prevalence across the world. Therefore, the drug development pipeline mostly contains therapeutic candidates for the treatment of ADPKD. This, coupled with the recent approvals, and special drug designations will drive the growth of the market segment during the forecast period.

Segmentation by Distribution Channels

  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics 

Globally, pain and inflammation management treatment type segment is expected to experience highest demand, as it is the first line treatment for autosomal dominant polycystic kidney disease. Kidney failure management treatment type segment is expected to contribute considerable market share in the global autosomal dominant polycystic kidney disease treatment market due to high prescription rates. Among all three distribution channels hospitals segment is expected to contribute highest revenue share in the global autosomal dominant polycystic kidney disease treatment market due to high patient pool.

Geographical Analysis

North America region holds the largest market share in the global polycystic kidney disease market

Geographically, the global polycystic kidney disease treatment market is segmented into regions, namely North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is expected to be a leading regional market for polycystic kidney disease treatment owing to increasing inclination of patients towards early diagnosis and treatment, and favourable reimbursement policies. Strong geographical presence of the leading players in the region is also expected to drive the growth of the polycystic kidney disease treatment market in North America.

Additionally, Europe is expected to account second large share in the global polycystic kidney disease treatment market. However, APEJ polycystic kidney disease treatment market is expected to record a robust CAGR growth attributed to increasing awareness and rising number of patient suffering from kidney disease. Furthermore, geographical expansion of major players is also a significant factor propelling the polycystic kidney disease treatment market.

Competitive Landscape

Some of the key participants operating in the global polycystic kidney disease treatment market are Merck & Co., Inc., Par Pharmaceutical Companies, Inc., Silvergate Pharmaceuticals Inc., Valeant Pharmaceuticals, Inc., Palladio Biosciences Pharmaceutical Industries Ltd, Mylan Pharmaceuticals Inc., AstraZeneca, etc.

To remain in the forefront of the competitive market, the leading market players are focusing on expanding their geographical presence and investing in product development The adoption of organic as well as inorganic strategies by the players help the polycystic kidney disease treatment market to grow at a significant growth rate.

Among the 10EM, China accounts for the largest market size of polycystic kidney disease, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Nicotinamide Diabetes Intervention Trial (ENDIT) study showed that large doses of niacinamide are safe in humans. Additionally, niacinamide is a dietary supplement, and therefore does not require approval by the FDA, although a pivotal trial would help to establish an optimal dosage regimen.

Xortyx, the company developing a proprietary formulation of oxypurinol is in phase 2/3 clinical trial in 2019.

Global Polycystic Kidney Disease Market – Key Companies to Watch

B. Braun Melsungen AG

Overview: B. Braun is German company that manufactures medical and pharmaceuticals device. Headquartered in Melsungen, Germany and founded in 1839. They provide services in around 60 countries that employees around 63,000 people. They have aroubd 5,000 variety of healthcare products.

Product Portfolio:

Dialog iQ:  this system has 2 biological inputs that are designed to provide information on hemodynamic condition of patient’s.

Key Developments: B. Braun acquired Intermedt Medizin & Technik GmbH, that will work for preparation of dialysis concentrates.

The global polycystic kidney disease market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topic’s

Kidney Cancer and Renal Cell Carcinoma Drugs Market

Kidney Stone Management Devices Market

Chronic Kidney Disease Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest